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Background: Preterm birth is the most important single determinant of adverse outcome in the United Kingdom;
one in every 70 babies (1.4%) is born before 32 weeks (very preterm), yet these births account for over half of
infant deaths.
Deferring cord clamping allows blood flow between baby and placenta to continue for a short time. This often
leads to increased neonatal blood volume at birth and may allow longer for transition to the neonatal circulation.
Optimal timing for clamping the cord remains uncertain, however. The Cochrane Review suggests that deferring
umbilical cord clamping for preterm births may improve outcome, but larger studies reporting substantive
outcomes and with long-term follow-up are needed. Studies of the physiology of placental transfusion suggest that
flow in the umbilical cord at very preterm birth may continue for several minutes. This pilot trial aims to assess the
feasibility of conducting a large randomised trial comparing immediate and deferred cord clamping in the UK.
Methods/Design: Women are eligible for the trial if they are expected to have a live birth before 32 weeks
gestation. Exclusion criteria are known monochorionic twins or clinical evidence of twin-twin transfusion syndrome,
triplet or higher order multiple pregnancy, and known major congenital malformation. The interventions will be
cord clamping within 20 seconds compared with cord clamping after at least two minutes. For births with cord
clamping after at least two minutes, initial neonatal care is at the bedside. For the pilot trial, outcomes include
measures of recruitment, compliance with the intervention, retention of participants and data quality for the
clinical outcomes.
Information about the trial is available to women during their antenatal care. Women considered likely to have a
very preterm birth are approached for informed consent. Randomisation is close to the time of birth. Follow-up for
the women is for one year, and for the children to two years of age (corrected for gestation at birth). The target
sample size is 100 to 110 mother-infant pairs recruited over 12 months at eight sites.
Trial registration: ISRCTN21456601, registered on 28 February 2013.
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In the UK, infant mortality (deaths in the first year of
life) for babies born very preterm (before 32 weeks ges-
tation) is 144/1000 live births, compared to 1.8/1000 for
those born at term (38 to 41 weeks) [1]. Very preterm
birth accounts for 1.4% of live births in the UK, but 51%
of infant deaths [1]. For infants born before 28 weeks,
duration of hospital stay is 85 times longer than for term
births, and hospital inpatient costs are £15,000 higher;
for those born at 28 to 31 weeks, it is 16 times longer
and £12,000, respectively [2].
Morbidity amongst children born very preterm is
also high compared to those born at term. Of very pre-
term infants who survive, 5 to 10% develop cerebral
palsy, and those without severe disability have a twofold or
greater increased risk for developmental, cognitive, and be-
havioural difficulties [3,4]. Of babies born before 28 weeks,
a quarter of survivors have neurosensory disability, such as
cerebral palsy, severe developmental delay, blindness or
deafness [5]. Surviving children have higher levels of dys-
function in a range of measures of cognition, behaviour and
functioning [5], impairments that persist into adolescence
and early adulthood [6,7]. Teenagers and young adults born
very preterm also report poorer physical abilities and more
chronic ill health and functional limitation than their peers
born at term, although self-reporting of health-related qual-
ity of life is similar [8,9]. Prematurity and its sequelae have
an enormous negative psychosocial and emotional impact
on parents and families [5,10].
Placental transfusion
Placental transfusion is the transfer of blood between
the placenta and the baby at birth. For term births, this
blood flow is usually complete by two minutes, but may
continue for up to five minutes. The mean volume of
placental transfusion for term births is 100 ml, which is
around 29 ml/kg birth weight and 36% of neonatal blood
volume at birth [11]. For preterm births, placental trans-
fusion may take longer [12], and may be incomplete if
the cord is clamped within 30 to 90 seconds [13]. This
seems logical, as at term, two-thirds of the feto-placental
circulation is in the infant, whilst below 30 weeks gesta-
tion, a greater proportion is in the placenta [14]. Also,
the umbilical vein is smaller than at term, and uterine
contraction less efficient. Cord clamping before placental
transfusion is complete may restrict neonatal blood vol-
ume and red cell mass, and interrupt transition from the
fetal to neonatal circulation.
As the baby is born, umbilical circulation slows and
pulmonary vascular resistance falls, rapidly increasing
pulmonary blood flow. This is the beginning of transi-
tion from the fetal to the neonatal circulation. For
infants born too early, the mechanisms for these circu-
latory changes may not be fully developed and so maytake longer. Continued flow in the umbilical vein and
arteries at birth may be part of the physiological mech-
anisms assisting the baby as it makes the transition
from fetal to neonatal circulation. Restricting this flow
by immediate cord clamping may limit the baby’s abil-
ity to deal with this transition. If there is insufficient
circulating blood volume to fill the expanding pulmon-
ary vasculature, an infant may compensate by reducing
flow to the peripheral circulation and/or to organs such
as the kidney. Whilst most healthy babies at term may
adapt without major consequences, for those born preterm
or with their cardio-respiratory circulation already im-
paired, there may be substantive consequences.
Over 20 years ago it was first suggested that restricting
placental transfusion by immediate clamping for preterm
babies might increase the risk of intraventricular haem-
orrhage [15]. Possible mechanisms for this increase were
suggested to be hypovolaemia, and/or increased fluctu-
ation in blood pressure following the abrupt transition
to a neonatal circulation.
Cord milking (pinching the cord close to the mother
and running the fingers towards the baby, usually several
times) has been suggested for preterm births as a means
to increase neonatal blood volume without deferring
cord clamping [16]. Cord milking over-rides the infant's
physiological control of its own blood volume and blood
pressure, however, and disrupts umbilical blood flow.
Systematic review: immediate versus deferred cord clamping
The Cochrane Review of timing of cord clamping for
preterm births [17] includes 15 trials, with 738 infants
recruited between 24 and 36 weeks gestation. Immedi-
ate cord clamping ranged from 5 to 20 seconds, al-
though several studies did not state the duration.
Deferred clamping ranged from 31 to 120 seconds for
births before 34 weeks; one study recruiting between
34 weeks and 36 weeks gestation used 180 seconds.
The few studies that reported a rationale for how long
to defer clamping said it had been a balance between
allowing placental transfusion, and what was perceived
as an acceptable delay in neonatal care. One small trial
(40 mother-infant pairs) compared cord milking with
immediate cord clamping [16]. Many outcomes are re-
ported by only a few studies, so there is potential for
reporting bias.
No trials reported outcome for the women. Primary
outcomes for the infants were death, death or neurodi-
sability at two years of age, ultrasound diagnosis of
grade 3 or 4 intraventricular haemorrhage, and peri-
ventricular leukomalacia. Death before discharge from
hospital was reported in 13 trials, and there was no
clear difference between the groups (Table 1). No stud-
ies have reported death or neurodisability at two years
of age. There was no clear difference between the
Table 1 Immediate versus deferred cord clamping for preterm births: effects for infants
Outcome Number of trials Number of participants Risk ratio 95% confidence interval
Death 13 668 0.63 0.31 to 1.28
intraventricular haemorrhage
any (grade 1 to 4)) 10 539 0.59 0.41 to 0.85
severe (grade 3 or 4) 6 305 0.68 0.23 to 1.96
periventricular leukomalacia 2 71 1.02 -0.52 to 5.56
temperature on SCBU admission (°C)a 3 143 0.14a -0.03 to 0.31a
Transfusion
for anaemia 7 392 0.61 0.46 to 0.81
for hypotension 4 130 0.52 0.24 to 1.11
number of transfusionsa 5 210 -1.26a -1.87 to −0.64a
mean arterial pressurea
at birth 2 97 3.52a 0.60 to 6.45a
at 4 hours 2 111 2.49a 0.26 to 4.72a
inotropes for low blood pressure 4 158 0.42 0.23 to 0.77
necrotising enterocolitis 5 241 0.62 0.43 to 0.90
serum bilirubin peaka 7 320 15.01a 5.62 to 24.40a
jaundice requiring phototherapy 3 180 1.21 0.94 to 1.55
oxygen supplementation at 36 weeks 5 209 0.69 0.42 to 1.13
amean difference.
SCBU, special care baby unit.
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or periventricular leukomalacia.
Infants allocated to deferred cord clamping had
fewer diagnoses of any intraventricular haemorrhage
than those allocated to immediate clamping (Table 1).
There was no clear difference between the groups in
the three trials reporting temperature on admission to
the special care baby unit. Deferred cord clamping was
associated with less transfusion for anaemia, but there
was no clear difference in transfusion for hypotension.
Deferred clamping was also associated with higher
mean arterial blood pressures at birth and at four
hours of age, and less requirement for inotropes. It was
also associated with a reduction in the risk of necrotising
enterocolitis. Infants allocated deferred cord clamping had
higher serum bilirubin, but there was no clear difference in
jaundice requiring phototherapy in the three trials
reporting this outcome. There was no clear difference
between the groups in oxygen requirement at 36 weeks
postmenstrual age.
Follow-up at age seven months (corrected for gesta-
tion at birth) was reported for one study, which re-
cruited 72 infants. Of these, five died before seven
months and nine were lost to follow-up. There was no
overall difference between the groups in Bayley Scales
of Infant Development-II.
The review concludes that ‘to reliably compare strat-
egies for influencing placental transfusion we need largehigh-quality trials, with sufficient power to reliably assess
clinically relevant differences in important outcomes’ [17].
Initial care at birth for very preterm infants: at the
bedside or at the room side
Initial neonatal care and stabilisation takes place on a
resuscitaire. Traditionally, this is at the side of the room,
or in an adjacent room. Disadvantages of these locations
are that they necessitate immediate cord clamping, and
that often the woman and her partner are not able to
see or touch their baby at birth [18,19]. If cord clamping
is deferred this should not necessarily mean that neo-
natal care is also deferred. Strategies for providing neo-
natal care and stabilisation of the baby at the bedside
have now been developed. Parents’ views following initial
care at the bedside have been positive [20]. Evaluation of
the views of clinicians is also positive, although there are
initial issues around training, practical arrangements for
preparing and moving the equipment, and making space
at the bedside [20]. The experience of providing initial
neonatal care at the bedside has been positive, and it is
now part of standard care in some hospitals.
Providing neonatal care for very premature infants at
the bedside allows the woman and her partner to share
the first moments of their child’s life [21,22], if they wish
to, and is therefore potentially a more family-centred
approach. Family-centred care in neonatal units, with
improved communication and involvement of parents in
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by parents [10] and is an NHS priority [23]. Providing
neonatal care at the bedside has parallels with family
presence during resuscitation of adults and children,
which is preferred by families and appears to be benefi-
cial [24-28].
Current practice for timing of cord clamping at very
preterm births
In the UK, 57% of obstetricians report clamping the
cord within 20 seconds for very preterm births [29].
Just 15% of midwives and 5% of obstetricians reported
that they routinely record when the cord was clamped
in the medical notes. Guidelines for care during the
third stage of labour make various recommendations,
and it is often not clear how these should be applied to
very preterm babies, many of whom will require neonatal
care at birth [30-32].
Why a trial is needed now
Current evidence is that for very preterm births, timing
of cord clamping, and other strategies to influence pla-
cental transfusion, may improve outcome at hospital.
But the trials are small, and overall there is high risk of
bias. The effects on substantive outcomes and long-term
neurodevelopment remain uncertain. Assessing alterna-
tive strategies for timing of cord clamping has been
identified as a research priority by service users [33], re-
searchers [17,34,35], obstetricians [29], midwives [29],
neonatologists (Duley L, Farrar D, McGuire W, Oddie S:
Survey of the Extended Neonatal Network to assess
views on timing of cord clamping and placental transfusion,
unpublished), NICE [30,36], and the Royal College of
Obstetricians and Gynaecologists [21].
Our primary hypothesis is that for children born before
32 weeks gestation immediate cord clamping is associated
with higher death or neurosensory disability at two years of
age (corrected for gestation at birth) than deferred cord
clamping. A trial to test this hypothesis would need to be
large and multicentre. This protocol is for a pilot trial
to assess the feasibility such a study.
Methods/Design
This study is a pragmatic multicentre pilot randomised
trial comparing alternative strategies for cord clamping
at very preterm birth.
Participants
Women are eligible for the study if they are expected
to have a live birth before 32 weeks gestation, regard-
less of mode of birth or whether cephalic or breech
presentation.
Exclusion criteria are monochorionic twins (from an
ultrasound scan) or clinical evidence of twin-twintransfusion syndrome, triplets or higher order multiple
pregnancy, or known major congenital malformation.
Interventions
There is no consensus about the definition of immediate
or deferred cord clamping, or about the optimal timing
of cord clamping for very preterm birth. We have
chosen our interventions based on current practice
[29], the interventions reported in the trials included
in the Cochrane review [17], consultation with neona-
tologists, and our work measuring the volume and
duration of placental transfusion [11,37].
The interventions are cord clamping within 20 seconds
or cord clamping after at least two minutes.
For both groups, while the cord is intact, the baby should
be at the level of the placenta, and should not be lifted
above the level of the mothers’ abdomen. All other aspects
of care are at the discretion of the attending clinicians, in-
cluding administration of a prophylactic uterotonic drug.
For deferred cord clamping, care for the baby is pro-
vided at the mother’s bedside. For immediate clamping
care is either at the bedside or at the side of the room,
at the discretion of the attending clinicians. In both
cases the baby receives the same care at birth, just in dif-
ferent places. Neonatal care is based on local unit policy
and consistent with newborn life support guidelines
[32,38]. Standard equipment is used for both groups ac-
cording to local practice, including plastic sheets or bags
(depending on gestation and local practice), towels and
any other equipment such as hats, warming mattress or
overhead heaters, and saturation monitors.
For neonatal care at the bedside, babies are placed onto a
firm surface next to the mother’s bed or to the operating
theatre table, with easy access to necessary equipment. This
is achieved either by moving the conventional resuscitaire
alongside the woman’s bed [39] or by using a small specia-
lised mobile trolley (for example the BASICS trolley) [40].
Outcome measures
To assess the feasibility of a large multicentre trial, the
outcomes for this pilot trial are as follows:
1. number of women recruited in each hospital;
2. proportion of potentially eligible women recruited;
3. reasons for non-recruitment (medical, parental,
logistic, other);
4. spectrum of gestational age and neonatal outcome
among recruits;
5. compliance with the trial interventions, and reasons
for non-compliance;
6. completeness of data collection for main outcomes;
7. views of women and their partners on recruitment,
randomisation and the interventions’ and
8. proportion lost to follow.
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used in the main trial will also be collected. These
are death or neurosensory disability at age two years
(corrected for gestation at birth) as primary outcome.
Secondary outcomes for the baby are death, blood
transfusion, intraventricular haemorrhage (grade 3 to
4), periventricular leukomalacia, hypothermia, respira-
tory distress syndrome, ventilation, necrotizing entero-
colitis, treatment for hyperbilirubinemia, duration of
hospital stay and neurosensory delay at age 2 years
(corrected for gestation at birth).
Secondary outcomes for the women are postpartum
haemorrhage, infection, depression, and breast feeding/
expressing.
Outcome for the women is assessed at discharge from
hospital, by a self-completed (either handed out in hos-
pital or sent by post) questionnaire at four to eight
weeks, and by self-completed postal questionnaire at
one year. For the babies, outcome is assessed at 36 weeks
postmenstrual age, at discharge from hospital, and at age
2 years (corrected for gestation at birth). This assess-
ment at age two includes an Ages and Stages Question-
naire [41], the PARCA-R (Parent Report of Children’s
Abilities-revised) questionnaire [42], and a Bayley Scales
of Infant Development III [43]. This Bayley assessment
is blind to the allocated group.
Sample size
Eight large maternity hospitals are included in this pilot
trial, with an estimated total of 43,600 live births per
year (5 to 6,000 average annual live births per unit). In
the UK, 1.4% of live births are before 32 weeks gestation
[1]; we, therefore, expect 610 potentially eligible births
and anticipate recruitment of between 100 and 110
women (16 to 18% accrual) over 12 months.
Randomisation
Randomisation is in a 1:1 ratio, stratified by hospital.
Sequence generation uses computer-generated, random
permutated balanced blocks of randomly varying size,
created by the Nottingham Clinical Trials Unit (NCTU)
in accordance with their standard operating procedure.
Concealment of allocation is by sealed consecutively
numbered opaque envelopes. These envelopes are held
in a ring binder randomisation folder, which is kept in a
secure place that is easily accessible for the delivery
suite. Envelopes are removed in consecutive order by
tearing the next one out of the randomisation folder at
the punch holes. At the time of removing the folder,
whoever takes it initials and dates the folder log. On the
front of each envelope is a reminder to check eligibility,
and a label to be completed before the envelope is
opened. This label records the date, time, woman’s ini-
tials, her date of birth, and her gestation. Once thisinformation is complete, the woman is considered to be
randomised, even if the envelope is not opened.
The envelopes contain a yellow card stating when the
cord should be clamped; stickers for the woman and
baby’s medical notes (indicating they are in the trial);
and a Birth Record (plus a second to be used for twin
births) to be completed at the time of birth and filed in
the baby’s medical notes. The Birth Record asks for in-
formation about care during the third stage of labour
and initial neonatal care. Each delivery suite has a Cord
Pilot Trial secure mailbox. After each randomisation, the
randomisation envelope and the yellow allocation card
are posted into this mailbox. The mailbox is checked
daily by the research midwife/nurse. Details from the
randomisation envelope are then entered into the online
randomisation log maintained by the NCTU, and the en-
velope is filed with the woman’s Case Report Form.
If an envelope is taken from the randomisation folder
but not used, the discarded envelope is posted unopened
into the Cord Pilot Trial mailbox. These unused and dis-
carded envelopes are notified to NCTU, and the enve-
lopes returned to NCTU. All randomisation envelopes,
both opened and unopened, are accounted for by the
NCTU. Envelopes used out of order or tampered with
will be recorded and reported.
Trial entry and recruitment
General information about the trial, such as summary
information leaflets and study posters, is available on
antenatal clinics and antenatal wards. These introduce
the trial and explain how women can access more infor-
mation if they wish. To avoid causing unnecessary anx-
iety this information makes clear that only around 1 in
70 women give birth before 32 weeks gestation. Women
who would like more information are offered the parent
information sheet, which is more detailed.
Women in the antenatal clinics, antenatal wards or a
high risk antenatal clinic, who are at a high risk of hav-
ing a birth at less than 32 weeks gestation are offered
the parent information sheet. They have an opportunity
to discuss the study with their family and partner. If a
woman decides to participate in the trial, written in-
formed consent is taken. Whenever possible, at least
12 hours is given for the woman to consider participat-
ing in the trial. If a woman does not participate, this de-
cision will not influence her clinical care.
If a woman who has consented to participate in the
trial is in established labour, or is being prepared for a
caesarean section, her gestation and willingness to par-
ticipate are checked. If she still meets the inclusion
criteria she is randomised (Figure 1). Randomisation
near to the time of birth should ensure that women en-
rolled into the trial give birth before 32 weeks gestation.
However, if a woman is randomised but does not give
Woman in maternity unit and at risk of preterm birth 
Birth imminent
(preparing for caesarean section, or in established labour)
Check eligibility
RANDOMISATION
Immediate cord clamping
clamping within 20 seconds 
neonatal care at the roomside/ bedside
Deferred cord clamping
clamping after at least 2 minutes 
neonatal care at the bedside
Women: outcome at discharge Children: outcome at discharge
Women: follow-up at 12 months Children: follow-up at age 2 years 
(corrected for gestation at birth)
Woman gives consent 
(see flowchart 2)
Not eligible
No further contact
Check eligibility
Eligibility confirmed
Figure 1 Participant flow. This figure shows the participants’ pathway through the trial.
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the trial.
If there is insufficient time to gain written consent be-
fore randomisation, and the attending clinician feels it is
appropriate, these women will be asked verbally if they
would like to participate in the trial. After a brief sum-
mary of the study as well an opportunity to ask ques-
tions, the woman is asked if she would like to participate
in the trial. If she agrees, she is then randomised
(Figure 2). This is recorded in her medical notes, and
the clinician taking consent completes a form. Before
discharge from hospital, the woman is approached for
written consent to use her and her baby’s data, and for
participation in follow-up. If a woman declines oral
assent, she is not randomised.
This process for oral assent was developed in discus-
sion with the National Childbirth Trust (NCT) and Bliss,
the special care baby charity. It is also in line with rec-
ommendations on valid consent for research while in
labour from the Royal College of Obstetricians and
Gynaecologists [44].Follow-up of participants
At discharge from hospital, outcome data for the women
and babies are collected from the medical notes, along
with contact details to facilitate follow-up. Women are
asked to complete a questionnaire at four to eight weeks.
If the baby is still in hospital this is given to them by the
research midwife/nurse, or if the baby is no longer in
hospital, it is posted to their home address. The ques-
tionnaire includes the Hospital Anxiety and Depression
Scale (HADS) [45], questions asking the women about
their and her babies’ care and their experience in hos-
pital, and asks women about their experience of partici-
pating in the CORD Pilot trial. There is also a section
asking women about their baby’s feeding (removed if the
baby died). When the child is one year old, a birthday
card is sent along with a second questionnaire asking
the same questions. A stamped addressed envelope is
provided to return questionnaires.
When the baby is 2 years old (corrected for gestation
at birth), the parents/carers are contacted to arrange a
neurodevelopment assessment for the child, using the
Figure 2 Consent pathways. This figure shows the two different consent pathways used within the trial.
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this assessment, the family are sent the Ages and Stages
Questionnaire by post [41], and asked to complete and re-
turn this before the assessment (using a prepaid envelope).
The assessment is by a trained practitioner either at home
or in a clinic, whichever is preferred by the family. During
the visit, the parents are asked to complete the Parent Re-
port of Children’s Abilities - Revised (PARCA-R) [42].
For all questionnaires, if there is no response a reminder
is sent after two weeks. If there is still no response afteranother two weeks, the coordinating centre telephone to
offer the opportunity to complete the questionnaire over
the telephone. If no telephone number is available another
postal reminder is sent. Stamped addressed envelopes are
provided for all questionnaires.
Women and babies are also ‘flagged’ with the Health
and Social Care Information Centre, through the Medical
Research Information Service. This allows identification of
deaths after discharge from hospital and movement out of
the NHS, information that helps prevent inappropriate
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follow-up.
Adverse events
This study includes babies who are high risk for adverse
outcomes, and so adverse events that could be influ-
enced by the trial interventions are being collected as
outcomes for the study.
Although neonatal or infant death is one of the out-
comes for this study, death before discharge from hos-
pital is considered as a serious adverse event (SAE). Any
unexpected and serious adverse event, for either the
woman or the baby, considered to be potentially related
to the study interventions will also be reported as a SAE.
Any SAE that is not a death will be followed until there
is resolution or the event is considered stable.
All SAEs are reported to the Chief Investigator. The
Chief Investigator will submit, every six months for the
duration of recruitment to the trial or on request, a
safety report to the Data Monitoring Committee, which
will include all reported SAEs.
Site set-up and training
Site set-up and training includes a range of strategies,
such as collaborators meetings, site initiation visits,
video and simulations, slide sets, and site monitoring
visits. Training in providing neonatal care at the bedside
is provided for all clinical staff, including neonatologists,
obstetricians, and midwives.
Feasibility criteria for progression to the main trial
The final decision about progression to the main trial
will be made by the independent Trial Steering Commit-
tee, in consultation with the Data Monitoring Commit-
tee. The pre-specified criteria for feasibility are based on:
1. recruitment of at least 50% of target at 12 months.
But, if recruitment is below 80% of target, there will
need to be clear and achievable strategies for
overcoming identified barriers thereby improving
recruitment.
2. at least 80% of women in each group receiving the
intervention to which they had been allocated
during the final six months of recruitment (as
compliance may be lower in the early stages of a
feasibility study). For a proportion of births it is
anticipated that the cord will be too short to allow
initial care at the bedside, and so for these infants in
the deferred arm cord clamping may be before
2 minutes. For example, in a study requiring babies
to be placed on weighing scales with the cord intact,
of 33 term births for 5 (15%) the cord was too short
to allow the baby to be placed on the scales [11]. For
the deferred arm, feasibility criteria will beconsidered to be met if 80% of infants with adequate
cord length had cord clamping after at least
2 minutes.
3. the difference between the two groups in median
time to cord clamping is at least 45 seconds.
Data management and trial monitoring
Data are entered as they accumulate into a trial specific
database developed and maintained by the NCTU. Ac-
cess to the database will be restricted and secure. All
trial data are anonymised by use of unique participant
trial numbers. Data quality is checked using criteria for
out-of-range and consistency, and checks for conflicting
data within and between data collections forms. Missing
data and data queries are referred promptly back to the
recruiting site for clarification.
For the follow-up phase, identifiable information about
participants will be held in a separate database to the
trial data. Access to this information will be restricted to
those involved in the follow up phase, as authorised by
the Chief Investigator.
Trial monitoring is by central statistical monitoring
combined with site visits. Central statistical monitoring
is used to monitor patterns of recruitment at sites, rea-
sons for non-recruitment of potentially eligible women,
characteristics of women recruited, gestation at recruit-
ment, and time of recruitment. It is also to assess compli-
ance with the protocol, such as eligibility and compliance
with the trial interventions. Each site has at least one moni-
toring visit; timing of this visit is influenced by recruitment,
data quality, and compliance with the protocol and study
procedures.
The Chief Investigator is the custodian of the data.
The trial is conducted in compliance with the current
revision of the Declaration of Helsinki (last amendment
October 2008), with relevant regulations, and with MRC
Guidelines for Good Clinical Practice in Clinical Trials,
[46] which is based on International Conference on
Harmonisation (ICH) guidelines for good clinical prac-
tice (GCP) (CPMP/ICH/135/95) July 1996.
Data analysis
Eligibility, recruitment and retention through the study
will be presented in a CONSORT flow diagram to show
the number of eligible women, the number approached
for participation (split according to written consent and
oral assent), the number of women (and their babies)
randomised into the two groups, and completion of
follow-up of the outcomes for the main study. Reasons
for eligible women not providing consent and for those
who have given consent not being randomised will be
described, when known. The time between oral assent
and randomisation will be analysed to check that this
method of consent is being used appropriately. Reasons
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also be presented, where known.
Baseline characteristics of the women (age, previous preg-
nancy history, reason for preterm birth) and the baby at
birth (gestational age at birth, baby gender and birth
weight) will be presented descriptively split by allocated
group. Continuous data will be summarised in terms of the
mean, standard deviation and/or median, lower and upper
quartiles, minimum and maximum with the number of ob-
servations. Categorical data will be summarised in terms of
frequency counts and percentages. The number of missing
values will be presented where applicable.
Compliance with the intervention will be assessed by
summarising the median time to cord clamping in the
two groups, the difference in median time to cord
clamping between the two groups, and the proportion of
women receiving the allocated intervention. Reasons for
non-compliance with the allocated intervention will be
tabulated. Compliance will be assessed for the first six
months of recruitment and for the second six months,
as our hypothesis is that compliance will improve over
time. The number (and percentage) of babies receiving
bedside or room side care and the type of care given in
each location in the two groups will be described.
Outcomes will be described for women at discharge, at
four to eight weeks, at 1 year, and for babies at discharge
and at 2 years. Any unexpected serious adverse events
for either the women or the baby will also be described.
This description of outcome will be for both groups
combined, not by allocated group. If feasibility is demon-
strated, and the trial progresses to a main study outcome
by allocated group will remain confidential to the Data
Monitoring Committee. It would then contribute to the
sample size for the main trial.
The woman’s views about whether participation in the
Cord Pilot Trial will be tabulated overall, and split by char-
acteristics that may influence the women’s views about par-
ticipating in the study. These characteristics are pre-
specified as allocated group, death of the baby, whether oral
assent was used, maternal age at recruitment, gestation at
recruitment less than 30 weeks, severe post-partum haem-
orrhage, postnatal depression, length of stay in a special
care baby unit longer than six weeks and whether partici-
pants needed a reminder to complete the questionnaires.
Archiving
Data and all appropriate study documentation will be
stored for a minimum of 10 years after completion of
the trial, including the follow-up period. The trial master
file and trial documents held by the Chief Investigator
on behalf of the sponsor will be archived in secure arch-
ive facilities at Nottingham University Hospitals NHS
Trust. This archive will include all trial databases and as-
sociated meta-data encryption codes.Trial management
Day-to-day management of the trial is the responsibility of
the Trial Management Group (TMG), which meets at least
every two months and more often if required. Trial over-
sight is by an independent Trial Steering Committee. Safety
of trial participants is monitored an independent Data
Monitoring Committee, who report to the Trial Steering
Committee. Trial coordination is through the NCTU.
Ethics approval
Approval for this study was granted by the Nottingham 2
Research Ethics Committee (NRES reference 12/EM/0283).
Sponsor
Nottingham University Hospitals NHS Trust acts as the
main sponsor for this trial. Delegated responsibilities are
assigned to the NHS trusts taking part. Standard NHS
Indemnity applies.
Discussion
Recruitment to the Cord Pilot Trial began in March
2013 and will close on 28 February 2014. Assessment of
the feasibility outcomes when recruitment is complete
will inform the decision about progressing to a large
multicentre trial in the UK.
Trial status
Recruitment to the Cord Pilot Trial is ongoing. The feasi-
bility assessment is based on recruitment from 1 March
2013 to 28 February 2014. Recruitment is being continued
in pilot sites whilst main trial funding is sought.
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